Psioxus website
WebPsiOxus® platform technology is based on a tumour selective oncolytic adenovirus. Viruses are engineered to express a targeted payload, upon intravenous administration, into a broad range of carcinoma cell lines, but not to replicate, or deliver the payload in normal cells. Adenovirus is manufactured by infecting human embryonic kidney cells (HEK 293) which … WebJan 5, 2024 · Akamis Bio has raised a total of $132.5M in funding over 9 rounds. Their latest funding was raised on Jan 5, 2024 from a Debt Financing round. Akamis Bio is funded by 11 investors. Parker Institute for Cancer Immunotherapy and Westlake Village BioPartners are the most recent investors. Akamis Bio has acquired Hybrid BioSystems on Dec 16, 2010.
Psioxus website
Did you know?
WebDec 20, 2016 · Bristol-Myers Squibb Media: Ken Dominski, 609-252-5251 [email protected] or Investors: Tim Power, 609-252-7509 [email protected] Bill Szablewski, 609-252-5894 [email protected] or ... WebTo achieve our mission, we are developing a portfolio of Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics which aim to enable a patient’s own immune system to recognize, …
WebDec 14, 2024 · PsiOxus Therapeutics is now Akamis Bio! Today we also announced a $30M convertible note financing led by ARCH Venture … WebAug 11, 2024 · PsiOxus is a clinical-stage biotechnology company pioneering novel systemic immuno-oncology therapeutics capable of sustainably reprogramming the solid tumor …
WebPsiOxus Therapeutics Follow Location: United Kingdom Founded in 2010 Private Company "A merger of Hybrid Biosystems (Professor Len Seymour - Division of Cancer Studies, 1997) and Myotec Therapeutics in December 2010. Key Business: Development of non-traditional therapeutics for serious diseases.
WebJul 9, 2012 · PsiOxus’ lead clinical-stage candidate, MT-102, was originally developed by Myotec. The small molecule drug is an anabolic catabolic transforming agent (ACTA) in Phase II development for treating...
PsiOxus Therapeutics has changed its name to Akamis Bio. Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. dr sue bowmanWebApr 16, 2015 · PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company with a particular focus in immune therapeutics in oncology. PsiOxus has developed a patented platform of tumour-targeted delivery based on its oncolytic vaccine, enadenotucirev (EnAd). colors of the us marinesWebMay 28, 2015 · PsiOxus is currently planning a trial of its experimental virus-based treatment, enadenotucirev, with a checkpoint inhibitor in colorectal cancer—a tumor type that so far has not been responsive... colors of the universeWebWebsite. www.psioxus.com . Contact Information. Headquarters. Science Park 4-10 The Quadrant Abingdon, Abingdon, Oxfordshire, OX14 3YS, United Kingdom +44 1235835328. PsiOxus Therapeutics Profile and History . PsiOxus Therapeutics aims to be the worlds leading cancer gene therapy company, delivering medicines of value to patients with … dr sue a shook school el pasoWebAkamis Bio Ltd. PsiOxus Therapeutics Limited develops therapeutics for serious diseases. The Company provides biotechnology therapeutics for cancer tumour-targeted delivery … dr sudip chatterjeeWebDec 15, 2010 · PsiOxus Therapeutics has been formed through the merger of Hybrid Biosystems with Imperial Innovations Group portfolio company Myotec Therapeutics. Imperial Innovations is also leading a £3.6... dr sue brownWebPsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UK based biotechnology company developing innovative new treatments for cancer, has been granted a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for an orphan medicinal product designation of its oncolytic vaccine, enadenotucirev … colors of the stone